Roanoke Asset Management Corp NY reduced its stake in shares of Eli Lilly and Co (NYSE:LLY) by 15.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 27,970 shares of the company’s stock after selling 4,975 shares during the period. Roanoke Asset Management Corp NY’s holdings in Eli Lilly and were worth $2,353,000 as of its most recent filing with the SEC.
Other hedge funds have also recently modified their holdings of the company. First Command Financial Services Inc. increased its position in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock worth $103,000 after buying an additional 84 shares during the last quarter. Financial Architects Inc increased its position in shares of Eli Lilly and by 4.5% in the third quarter. Financial Architects Inc now owns 1,423 shares of the company’s stock worth $114,000 after buying an additional 61 shares during the last quarter. Tarbox Group Inc. increased its position in shares of Eli Lilly and by 0.7% in the third quarter. Tarbox Group Inc. now owns 1,539 shares of the company’s stock worth $124,000 after buying an additional 11 shares during the last quarter. LeJeune Puetz Investment Counsel LLC acquired a new position in shares of Eli Lilly and during the fourth quarter worth $136,000. Finally, Physicians Financial Services Inc. increased its position in shares of Eli Lilly and by 6.1% in the third quarter. Physicians Financial Services Inc. now owns 1,738 shares of the company’s stock worth $139,000 after buying an additional 100 shares during the last quarter. Institutional investors own 75.15% of the company’s stock.
Shares of Eli Lilly and Co (NYSE:LLY) traded up 0.13% during trading on Friday, hitting $78.40. 1,300,201 shares of the company’s stock were exchanged. The firm has a 50-day moving average price of $82.44 and a 200-day moving average price of $78.16. Eli Lilly and Co has a one year low of $64.18 and a one year high of $86.72. The stock has a market cap of $82.81 billion, a P/E ratio of 37.91 and a beta of 0.30. Eli Lilly and also was the target of some unusual options trading activity on Tuesday. Stock traders bought 15,956 put options on the stock. This is an increase of 743% compared to the average volume of 1,893 put options.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings data on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.96 by $0.02. The business had revenue of $5.23 billion for the quarter, compared to the consensus estimate of $5.22 billion. Eli Lilly and had a net margin of 12.90% and a return on equity of 24.74%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.83 EPS. Equities research analysts expect that Eli Lilly and Co will post $4.12 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, June 9th. Investors of record on Monday, May 15th will be issued a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.66%. The ex-dividend date of this dividend is Thursday, May 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 80.62%.
A number of brokerages have recently weighed in on LLY. Jefferies Group LLC restated a “buy” rating and issued a $97.00 target price (up previously from $95.00) on shares of Eli Lilly and in a research note on Saturday, March 11th. Citigroup Inc lifted their price target on shares of Eli Lilly and from $92.00 to $100.00 and gave the stock a “buy” rating in a report on Wednesday, April 19th. Zacks Investment Research raised shares of Eli Lilly and from a “hold” rating to a “buy” rating and set a $87.00 target price on the stock in a report on Friday, February 3rd. Morgan Stanley cut shares of Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 target price on the stock. in a report on Monday, April 17th. Finally, Vetr cut shares of Eli Lilly and from a “hold” rating to a “sell” rating and set a $74.30 target price on the stock. in a report on Tuesday, January 31st. Two equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Eli Lilly and currently has an average rating of “Buy” and an average price target of $87.56.
In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of the company’s stock in a transaction on Thursday, May 4th. The shares were sold at an average price of $82.76, for a total transaction of $2,069,000.00. Following the completion of the transaction, the senior vice president now directly owns 114,217 shares in the company, valued at $9,452,598.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the company’s stock in a transaction on Thursday, March 30th. The stock was sold at an average price of $84.67, for a total transaction of $17,780,700.00. Following the transaction, the insider now owns 124,690,804 shares of the company’s stock, valued at $10,557,570,374.68. The disclosure for this sale can be found here. Corporate insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Co and related companies with MarketBeat.com's FREE daily email newsletter.